Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D09HNR
|
|||
Former ID |
DAP000109
|
|||
Drug Name |
Telithromycin
|
|||
Synonyms |
Ketek; Levviax; TEL; HMR 3647; HMR3647; RU 66647; RU66647; HMR-3647; Ketek (TN); RU-66647; Telithromycin [USAN:BAN:INN]; Telithromycin (JAN/USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
Therapeutic Class |
Antibiotics
|
|||
Company |
Sanofi-Aventis
|
|||
Structure |
Download2D MOL |
|||
Formula |
C43H65N5O10
|
|||
Canonical SMILES |
CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)C)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
|
|||
InChI |
1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1
|
|||
InChIKey |
LJVAJPDWBABPEJ-PNUFFHFMSA-N
|
|||
CAS Number |
CAS 191114-48-4
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
633047, 12015022, 14767066, 14913885, 17181612, 34667812, 57410165, 79644204, 103323138, 111611540, 124766275, 126669903, 134224303, 135253289, 135692562, 139962352, 140277637, 141465063, 144205007, 144205756, 152198790, 160857220, 164765238, 175268627, 179150119, 210279153, 210281475, 223393880, 226396929, 247267318, 252401574
|
|||
ChEBI ID |
CHEBI:29688
|
|||
ADReCS Drug ID | BADD_D02146 | |||
SuperDrug ATC ID |
J01FA15
|
|||
SuperDrug CAS ID |
cas=191114484
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
Studied Microbe: Staphylococcus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Staphylococcus was increased by Telithromycin (p <= 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Bacteroides was not significantly changed by Telithromycin. | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Bifidobacterium was decreased by Telithromycin (p <= 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
Studied Microbe: Citrobacter
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Citrobacter was increased by Telithromycin. | |||
Studied Microbe: Enterobacter
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Enterobacter was increased by Telithromycin. | |||
Studied Microbe: Escherichia coli
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Escherichia coli was decreased by Telithromycin. | |||
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Klebsiella was increased by Telithromycin. | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Clostridium difficile
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Clostridium difficile was not significantly changed by Telithromycin. | |||
Studied Microbe: Peptostreptococcus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Peptostreptococcus was not significantly changed by Telithromycin. | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Enterococcus was decreased by Telithromycin. | |||
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Lactobacillus was decreased by Telithromycin (p <= 0.05). | |||
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces, saliva | |
Disease or Condition | Healthy | |||
Description | The abundance of Streptococcus was not significantly changed by Telithromycin. | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Mycobacteriales | ||||
Studied Microbe: Corynebacterium
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Saliva | |
Disease or Condition | Healthy | |||
Description | The abundance of Corynebacterium was decreased by Telithromycin (p <= 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
Studied Microbe: Veillonella
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces, saliva | |
Disease or Condition | Healthy | |||
Description | The abundance of Veillonella was not significantly changed by Telithromycin. |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bacterial 50S ribosomal RNA (Bact 50S rRNA) | Target Info | Binder | [3], [4] |
References | Top | |||
---|---|---|---|---|
REF 1 | Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol. 2005 Oct;8(5):510-7. | |||
REF 2 | Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother. 2000 Nov;46(5):741-9. | |||
REF 3 | An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47. | |||
REF 4 | Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44(9):915-34. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.